No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
UTHR240816C330000
- 14.10
- +1.35+10.59%
15min DelayClose Jul 22 16:00 ET
14.40High13.70Low
13.70Open12.75Pre Close3 Volume1.02K Open Interest330.00Strike Price4.22KTurnover35.53%IV3.45%PremiumAug 16, 2024Expiry Date2.63Intrinsic Value100Multiplier25DDays to Expiry11.47Extrinsic Value100Contract SizeAmericanOptions Type0.5676Delta0.0126Gamma23.18Leverage Ratio-0.2690Theta0.1211Rho13.16Eff Leverage0.3446Vega
Intraday
- 5D
- Daily
News
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 20.86% on an annualized basis producing an average annual return of 33.79%. Currently, United Therapeutics has
Is Now The Time To Put United Therapeutics (NASDAQ:UTHR) On Your Watchlist?
Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
Wells Fargo analyst Tiago Fauth maintains $United Therapeutics(UTHR.US)$ with a buy rating, and maintains the target price at $350.According to TipRanks data, the analyst has a success rate of 38.8%
Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $344
Leerink Partners analyst Roanna Ruiz maintains $United Therapeutics(UTHR.US)$ with a buy rating, and adjusts the target price from $338 to $344.According to TipRanks data, the analyst has a success
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing
Martine A Rothblatt, Director, Chairperson & CEO, on July 15, 2024, sold 7,200 shares in United Therapeutics (UTHR) for $2,355,544. Following the Form 4 filing with the SEC, Rothblatt has control
Comments
Jinta Hong, CFA
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
+7
82
7
$United Therapeutics(UTHR.US$
lol that is a shit ton of inside selling all at the end of June
lol that is a shit ton of inside selling all at the end of June
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
12
1
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
Are you a high net profit margin lover? So you will like these 1⃣2⃣ stocks with a net profit margin above 4⃣0⃣%
🇺🇸 Texas Pacific Land $Texas Pacific Land(TPL.US$ 63.3%
🇸🇪 Evolution $Evotec(EVO.US$ 59.3%
🇺🇸 CME Group $CME Group(CME.US$ 57.1%
🇺🇸 Visa $Visa(V.US$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR(RTMVY.US$ 54.8%
🇺🇸 Verisign $VeriSign(VRSN.US$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise(PME.US$ 49.8%
🇺🇸 NVidia $NVIDIA(NVDA.US$ 47.3%
🇺🇸 Mastercard $MasterCard(MA.US$ 45.1%
🇫🇷 GTT $GTT Communications, Inc.(GTTN.US$ 44.8% ...
🇺🇸 Texas Pacific Land $Texas Pacific Land(TPL.US$ 63.3%
🇸🇪 Evolution $Evotec(EVO.US$ 59.3%
🇺🇸 CME Group $CME Group(CME.US$ 57.1%
🇺🇸 Visa $Visa(V.US$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR(RTMVY.US$ 54.8%
🇺🇸 Verisign $VeriSign(VRSN.US$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise(PME.US$ 49.8%
🇺🇸 NVidia $NVIDIA(NVDA.US$ 47.3%
🇺🇸 Mastercard $MasterCard(MA.US$ 45.1%
🇫🇷 GTT $GTT Communications, Inc.(GTTN.US$ 44.8% ...
13
Read more
151652693 : There are many theories that do not touch the QE factor that caused the rise and harvest of global finance
151336027 :
151830249 :
151078437 :
151817588 :
View more comments...